美国FDA生物制品紫皮书数据库
(U.S. FDA Purple Book: Database of Licensed Biological Products)
商品名 申请号 产品号 BLA类型 非专利名称 剂型 给药途径 规格/剂量 产品形式 批准日期 申请人 市场状态 许可证状态 参考产品非专利名称 参考产品专利名称
Tecentriq Hybreza 761347 001 351(a) atezolizumab and hyaluronidase-tqjs Injection Subcutaneous 1,875MG/15ML; 30,000UNITS/15ML (125MG/2,000UNITS/ML) Single-Dose Vial 2024/09/12 Genentech, Inc. Rx Licensed
Tremfya 761061 003 351(a) guselkumab Injection Subcutaneous 200MG/2ML (100MG/ML) Autoinjector 2024/09/11 Janssen Biotech, Inc. Rx Licensed
Tremfya 761061 004 351(a) guselkumab Injection Subcutaneous 200MG/2ML (100MG/ML) Pre-Filled Syringe 2024/09/11 Janssen Biotech, Inc. Rx Licensed
Tremfya 761061 005 351(a) guselkumab Injection Intravenous 200MG/20ML (10MG/ML) Single-Dose Vial 2024/09/11 Janssen Biotech, Inc. Rx Licensed
Hercessi 761346 002 351(k) Biosimilar trastuzumab-strf For Injection Intravenous 420MG Multi-Dose Vial 2024/09/06 Accord BioPharma Inc. Rx Licensed trastuzumab Herceptin
Pavblu 761298 001 351(k) Biosimilar aflibercept-ayyh Injection Intravitreal 2MG/0.05ML Single-Dose Vial 2024/08/23 Amgen Inc. Rx Licensed aflibercept Eylea
Pavblu 761298 002 351(k) Biosimilar aflibercept-ayyh Injection Intravitreal 2MG/0.05ML Pre-Filled Syringe 2024/08/23 Amgen Inc. Rx Licensed aflibercept Eylea
Taltz 125521 003 351(a) ixekizumab Injection Subcutaneous 40MG/0.5ML Pre-Filled Syringe 2024/08/20 Eli Lilly and Company Rx Licensed
Taltz 125521 004 351(a) ixekizumab Injection Subcutaneous 20MG/0.25ML Pre-Filled Syringe 2024/08/20 Eli Lilly and Company Rx Licensed
Niktimvo 761411 001 351(a) axatilimab-csfr Injection Intravenous 50MG/ML Single-Dose Vial 2024/08/14 Incyte Corporation Rx Licensed
Nemluvio 761390 001 351(a) nemolizumab-ilto For Injection Subcutaneous 30MG Autoinjector 2024/08/12 Galderma Laboratories, L.P. Rx Licensed
Zarxio 125553 003 351(k) Biosimilar filgrastim-sndz Injection Intravenous, Subcutaneous 300MCG/ML Single-Dose Vial 2024/08/09 Sandoz Inc. Disc Licensed filgrastim Neupogen
Zarxio 125553 004 351(k) Biosimilar filgrastim-sndz Injection Intravenous, Subcutaneous 480MCG/1.6ML (300MCG/ML) Single-Dose Vial 2024/08/09 Sandoz Inc. Disc Licensed filgrastim Neupogen
Enzeevu 761382 001 351(k) Biosimilar aflibercept-abzv Injection Intravitreal 2MG/0.05ML Single-Dose Vial 2024/08/09 Sandoz Inc. Rx Licensed aflibercept Eylea
Enzeevu 761382 002 351(k) Biosimilar aflibercept-abzv Injection Intravitreal 2MG/0.05ML Pre-Filled Syringe 2024/08/09 Sandoz Inc. Rx Licensed aflibercept Eylea
Lymphir 761312 001 351(a) denileukin diftitox-cxdl For Injection Intravenous 300MCG Single-Dose Vial 2024/08/07 Citius Pharmaceuticals, Inc. Rx Licensed
tecelra 125789 001 351(a) afamitresgene autoleucel Suspension Intravenous 2.68 x 10^9 to 10 x 10^9 CELL/ML Bag 2024/08/01 Adaptimmune LLC Rx Licensed
Epysqli 761340 001 351(k) Biosimilar eculizumab-aagh Injection Intravenous 300MG/30ML (10MG/ML) Single-Dose Vial 2024/07/19 Samsung Bioepis Co., Ltd. Rx Licensed eculizumab Soliris
Vabysmo 761235 002 351(a) faricimab-svoa Injection Intravitreal 6MG/0.05ML (120MG/ML) Pre-Filled Syringe 2024/07/09 Genentech, Inc. Rx Licensed
Kisunla 761248 001 351(a) donanemab-azbt Injection Intravenous 350MG/20ML (17.5MG/ML) Single-Dose Vial 2024/07/02 Eli Lilly and Company Rx Licensed
当前数据更新日期:2024年12月22日,更多信息请点击此处查询美国FDA药品数据库

数据库说明:

©2006-2024 DrugFuture->U.S. FDA Purple Book